We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Rexahn

News List

Rexahn & BioSense Enter License Agreement contractpharma
April 17, 2019
To advance the development and commercialization of RX-3117 for pancreatic cancer and other cancers in Greater China...
Rexahn, Merck Partner for Cancer contractpharma
August 22, 2018
Rexahn Pharmaceuticals has entered into a clinical trial collaboration agreement with Merck to evaluate the combination of Rexahn’s RX-5902 and Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in a Phase 2 trial in patients with metastatic triple nega
Rexahn, Haichang collaborate for developing liver cancer treatment biospectrumasia
February 11, 2018
Any clinical trials conducted by Haichang will be designed to meet both U.S. and Chinese regulatory requirements.